Current and historical daily PE Ratio for Spago Nanomedical AB (
OSTO:SPAGO
) from 2012 to Jun 20 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Spago Nanomedical AB stock (OSTO:SPAGO) PE ratio as of Jun 20 2024 is 0.
More Details
Spago Nanomedical AB (OSTO:SPAGO) PE Ratio (TTM) Chart
Spago Nanomedical AB (OSTO:SPAGO) PE Ratio (TTM) Historical Data
View and export this data going back to 2012. Start your Free Trial
Total 1293
- 1
- 2
- 3
- 4
- 5
- 6
- 15
| Spago Nanomedical AB PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-20 | At Loss | 2024-04-15 | At Loss |
| 2024-06-19 | At Loss | 2024-04-12 | At Loss |
| 2024-06-18 | At Loss | 2024-04-11 | At Loss |
| 2024-06-17 | At Loss | 2024-04-10 | At Loss |
| 2024-06-14 | At Loss | 2024-04-09 | At Loss |
| 2024-06-13 | At Loss | 2024-04-08 | At Loss |
| 2024-06-12 | At Loss | 2024-04-05 | At Loss |
| 2024-06-11 | At Loss | 2024-04-04 | At Loss |
| 2024-06-10 | At Loss | 2024-04-03 | At Loss |
| 2024-06-07 | At Loss | 2024-04-02 | At Loss |
| 2024-06-05 | At Loss | 2024-03-28 | At Loss |
| 2024-06-04 | At Loss | 2024-03-27 | At Loss |
| 2024-06-03 | At Loss | 2024-03-26 | At Loss |
| 2024-05-31 | At Loss | 2024-03-25 | At Loss |
| 2024-05-30 | At Loss | 2024-03-22 | At Loss |
| 2024-05-29 | At Loss | 2024-03-21 | At Loss |
| 2024-05-28 | At Loss | 2024-03-20 | At Loss |
| 2024-05-27 | At Loss | 2024-03-19 | At Loss |
| 2024-05-24 | At Loss | 2024-03-18 | At Loss |
| 2024-05-23 | At Loss | 2024-03-15 | At Loss |
| 2024-05-22 | At Loss | 2024-03-14 | At Loss |
| 2024-05-21 | At Loss | 2024-03-13 | At Loss |
| 2024-05-20 | At Loss | 2024-03-12 | At Loss |
| 2024-05-17 | At Loss | 2024-03-11 | At Loss |
| 2024-05-16 | At Loss | 2024-03-08 | At Loss |
| 2024-05-15 | At Loss | 2024-03-07 | At Loss |
| 2024-05-14 | At Loss | 2024-03-06 | At Loss |
| 2024-05-13 | At Loss | 2024-03-05 | At Loss |
| 2024-05-10 | At Loss | 2024-03-04 | At Loss |
| 2024-05-08 | At Loss | 2024-03-01 | At Loss |
| 2024-05-07 | At Loss | 2024-02-29 | At Loss |
| 2024-05-06 | At Loss | 2024-02-28 | At Loss |
| 2024-05-03 | At Loss | 2024-02-27 | At Loss |
| 2024-05-02 | At Loss | 2024-02-26 | At Loss |
| 2024-04-30 | At Loss | 2024-02-23 | At Loss |
| 2024-04-29 | At Loss | 2024-02-22 | At Loss |
| 2024-04-26 | At Loss | 2024-02-21 | At Loss |
| 2024-04-25 | At Loss | 2024-02-20 | At Loss |
| 2024-04-24 | At Loss | 2024-02-19 | At Loss |
| 2024-04-23 | At Loss | 2024-02-16 | At Loss |
| 2024-04-22 | At Loss | 2024-02-15 | At Loss |
| 2024-04-19 | At Loss | 2024-02-14 | At Loss |
| 2024-04-18 | At Loss | 2024-02-13 | At Loss |
| 2024-04-17 | At Loss | 2024-02-12 | At Loss |
| 2024-04-16 | At Loss | 2024-02-09 | At Loss |
Spago Nanomedical AB (OSTO:SPAGO) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Spago Nanomedical AB
ISIN : SE0004899474
Compare
Compare
Traded in other countries / regions
SPAGO.Sweden7UX.Germany IPO Date
2012-12-27Description
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through previous detection of tumors and metastases. The Tumorad products focuses on the development of a completely new form of radionuclide therapy for tumor selective radiation therapy of cancer. The company development projects are based on a platform of polymeric materials with varoious properties for precise diagnosis and treatment of life threatening and debilitating diseases.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers